ADGRF5. also known as GPR116. is a member of the adhesion G protein-coupled receptor (GPCR) family, characterized by its large extracellular N-terminal domains involved in cell-cell and cell-matrix interactions. It plays a role in diverse physiological processes, including lung surfactant homeostasis, metabolic regulation, and cancer progression. ADGRF5 antibodies are essential tools for studying the receptor's expression, localization, and functional mechanisms in tissues and cellular models. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry, and flow cytometry to detect ADGRF5 protein levels or monitor its activation states. Research has linked ADGRF5 dysregulation to diseases like pulmonary alveolar proteinosis, obesity, and breast cancer, underscoring its potential as a therapeutic or diagnostic target. Validated ADGRF5 antibodies are critical for ensuring specificity, particularly given the structural complexity of adhesion GPCRs and their splice variants. Many commercial antibodies target epitopes within the extracellular or intracellular domains, enabling researchers to investigate receptor shedding, signaling pathways, or interactions with ligands like surfactant protein D. Recent studies also explore ADGRF5's role in immune modulation and tissue remodeling, highlighting its broader relevance in pathophysiology. Proper validation using knockout controls or functional assays remains crucial to avoid off-target artifacts in experimental data.